This story analyzes proposed legislation that is being considered for a US regulatory approval pathway for biogenerics;cheaper versions of first generation biotechnology drugs. The legislation clearly favors big biotech and is something of a red herring in the almost decade-long debate over biogenerics. If passed, the legislation will prevent biogeneric manufacturers from competing with companies that currently possess monopoly-like franchises for many blockbuster biopharmaceutical products.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments